U.S., Jan. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07318051) titled 'Sample Collection for Ongoing Research and Product Evaluation (SCORE) Study' on Dec. 19, 2025.
Brief Summary: The SCORE study is a prospective, multi-site clinical trial designed to collect blood and tissue samples, along with relevant clinical data, from participants diagnosed with various solid tumors. The collected specimens and information will be used to evaluate the clinical performance of Natera's molecular residual disease (MRD) testing across multiple cancer types. The study aims to assess the ability of Natera's assays to detect circulating tumor DNA (ctDNA) as a marker for disease recurrence and treatment response.
Study ...